Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dmitry V Shcheblyakov

Showing results (21-30 of 34) with videos related to

Pageof 4
Sort By:
Frontiers in Immunology|March 3, 2023
Single-domain antibody delivery using an mRNA platform protects against lethal doses of botulinum neurotoxin AEugenia A Panova, Denis A Kleymenov, Dmitry V Shcheblyakov, et al.
Frontiers in Immunology|March 14, 2022
Single-Domain Antibodies Efficiently Neutralize SARS-CoV-2 Variants of ConcernIrina A Favorskaya, Dmitry V Shcheblyakov, Ilias B Esmagambetov, et al.
Vox Sanguinis|March 18, 2021
Impact of pathogen reduction methods on immunological properties of the COVID-19 convalescent plasmaAlexander I Kostin, Maria N Lundgren, Andrey Y Bulanov, et al.
Vaccines|January 28, 2026
Development of an mRNA Vaccine for Tick-Borne Encephalitis: Selection of a Prototype Virus StrainMaria A Nikiforova, Vladimir A Gushchin, Denis A Kleymenov, et al.
Frontiers in Immunology|September 29, 2025
Immunization route-mediated differences in long-term maturation of humoral immune response induced by adenovirus vector-based COVID-19 vaccine Sputnik V in nonhuman primatesAmir I Tukhvatulin, Ilya V Gordeychuk, Alina S Dzharullaeva, et al.
International Journal of Biological Macromolecules|June 21, 2025
Ultra-potent RBM-specific single-domain antibody broadly neutralizes multiple SARS-CoV-2 variants with picomolar activityDmitry V Shcheblyakov, Irina A Favorskaya, Inna V Dolzhikova, et al.
Vaccines|December 24, 2025
Adenoviral Vectors Expressing Optimized preM/E Genes of WNV Deliver Long-Term Protection Against Lethal West Nile Virus ChallengeTatiana A Ozharovskaia, Olga V Zubkova, Elizaveta V Korobova, et al.
Frontiers in Immunology|August 21, 2023
Safety and immunogenicity of rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine against SARS-CoV-2 in healthy adolescents: an open-label, non-randomized, multicenter, phase 1/2, dose-escalation studyAmir I Tukhvatulin, Inna V Dolzhikova, Alina S Dzharullaeva, et al.
Vaccines|August 6, 2021
Neutralizing Activity of Sera from Sputnik V-Vaccinated People against Variants of Concern (VOC: B.1.1.7, B.1.351, P.1, B.1.617.2, B.1.617.3) and Moscow Endemic SARS-CoV-2 VariantsVladimir A Gushchin, Inna V Dolzhikova, Alexey M Shchetinin, et al.
The Lancet Regional Health. Europe|November 8, 2021
An open, non-randomised, phase 1/2 trial on the safety, tolerability, and immunogenicity of single-dose vaccine "Sputnik Light" for prevention of coronavirus infection in healthy adultsAmir I Tukhvatulin, Inna V Dolzhikova, Dmitry V Shcheblyakov, et al.
Pageof 4

Showing results (21-30 of 34) with videos related to

Sort By:
Pageof 4
Frontiers in Immunology|March 3, 2023
Single-domain antibody delivery using an mRNA platform protects against lethal doses of botulinum neurotoxin AEugenia A Panova, Denis A Kleymenov, Dmitry V Shcheblyakov, et al.
Frontiers in Immunology|March 14, 2022
Single-Domain Antibodies Efficiently Neutralize SARS-CoV-2 Variants of ConcernIrina A Favorskaya, Dmitry V Shcheblyakov, Ilias B Esmagambetov, et al.
Vox Sanguinis|March 18, 2021
Impact of pathogen reduction methods on immunological properties of the COVID-19 convalescent plasmaAlexander I Kostin, Maria N Lundgren, Andrey Y Bulanov, et al.
Vaccines|January 28, 2026
Development of an mRNA Vaccine for Tick-Borne Encephalitis: Selection of a Prototype Virus StrainMaria A Nikiforova, Vladimir A Gushchin, Denis A Kleymenov, et al.
Frontiers in Immunology|September 29, 2025
Immunization route-mediated differences in long-term maturation of humoral immune response induced by adenovirus vector-based COVID-19 vaccine Sputnik V in nonhuman primatesAmir I Tukhvatulin, Ilya V Gordeychuk, Alina S Dzharullaeva, et al.
International Journal of Biological Macromolecules|June 21, 2025
Ultra-potent RBM-specific single-domain antibody broadly neutralizes multiple SARS-CoV-2 variants with picomolar activityDmitry V Shcheblyakov, Irina A Favorskaya, Inna V Dolzhikova, et al.
Vaccines|December 24, 2025
Adenoviral Vectors Expressing Optimized preM/E Genes of WNV Deliver Long-Term Protection Against Lethal West Nile Virus ChallengeTatiana A Ozharovskaia, Olga V Zubkova, Elizaveta V Korobova, et al.
Frontiers in Immunology|August 21, 2023
Safety and immunogenicity of rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine against SARS-CoV-2 in healthy adolescents: an open-label, non-randomized, multicenter, phase 1/2, dose-escalation studyAmir I Tukhvatulin, Inna V Dolzhikova, Alina S Dzharullaeva, et al.
Vaccines|August 6, 2021
Neutralizing Activity of Sera from Sputnik V-Vaccinated People against Variants of Concern (VOC: B.1.1.7, B.1.351, P.1, B.1.617.2, B.1.617.3) and Moscow Endemic SARS-CoV-2 VariantsVladimir A Gushchin, Inna V Dolzhikova, Alexey M Shchetinin, et al.
The Lancet Regional Health. Europe|November 8, 2021
An open, non-randomised, phase 1/2 trial on the safety, tolerability, and immunogenicity of single-dose vaccine "Sputnik Light" for prevention of coronavirus infection in healthy adultsAmir I Tukhvatulin, Inna V Dolzhikova, Dmitry V Shcheblyakov, et al.
Pageof 4